Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells

URN to cite this document:: urn:nbn:de:bvb:355-epub-530879
DOI to cite this document:: 10.5283/epub.53087

Holzinger, Astrid ; Abken, Hinrich

License: Creative Commons Attribution 4.0
PDF - Published Version
(620kB)

Date of publication of this fulltext: 21 Oct 2022 06:22

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Background: Adoptive therapy with genetically modified T cells achieves spectacular remissions in advanced hematologic malignancies. In contrast to conventional drugs, this kind of therapy applies viable autologous T cells that are ex vivo genetically engineered with a chimeric antigen receptor (CAR) and are classified as advanced therapy medicinal products. Summary: As “living drugs,” CAR T ...